Zentalis Pharmaceuticals, Inc.

Equities

ZNTL

US98943L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
11.98 ^USD	+2.61%		-3.66%	-20.96%

05-08	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	MT
05-07	Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 27, 2024 at 12:08 pm

Zentalis Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 292.19 million compared to USD 236.81 million a year ago. Basic loss per share from continuing operations was USD 4.47 compared to USD 4.48 a year ago.

Latest news about Zentalis Pharmaceuticals, Inc.

Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating	05-08	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	04-11	CI
Zentalis Pharmaceuticals, Inc. Announces CFO Changes	04-11	CI
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024	04-02	CI
Wedbush Raises Zentalis Pharmaceuticals' PT to $15 From $12, Tweaks Financing Assumptions, Says Still on Track to Share Multiple Azenosertib Datasets in 2024, 2025; Keeps Neutral Rating	02-28	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Zentalis Pharmaceuticals Names Chief Medical Officer, Chief Business Officer	01-25	MT
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	01-25	CI
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating	01-23	MT
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	01-08	CI
UBS Adjusts Zentalis Pharmaceuticals Price Target to $28 From $52, Maintains Buy Rating	11-28	MT
Zentalis Pharmaceuticals Insider Bought Shares Worth $167,943, According to a Recent SEC Filing	11-13	MT
Transcript : Zentalis Pharmaceuticals, Inc. - Special Call	11-10
North American Morning Briefing : Traders Await -2-	11-09	DJ
Wedbush Downgrades Zentalis Pharmaceuticals to Neutral From Outperform After Announced Updates to Azenosertib Strategy in Platinumsensitive Ovarian Cancer; Cuts PT to $12 From $38	11-08	MT
Stifel Cuts Price Target on Zentalis Pharmaceuticals to $36 From $44, Maintains Buy Rating	11-07	MT
HC Wainwright Lowers Price Target on Zentalis Pharmaceuticals to $46 From $55, Maintains Buy Rating	11-07	MT
Morgan Stanley Adjusts Price Target on Zentalis Pharmaceuticals to $38 From $55, Maintains Overweight Rating	11-07	MT
Zentalis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Zentalis Pharmaceuticals, Inc. Announces Executive Changes	11-06	CI
Zentalis Pharmaceuticals Chief Operating Officer to Depart	09/10/23	MT
Zentalis Pharmaceuticals Insider Sold Shares Worth $106,926, According to a Recent SEC Filing	09/10/23	MT
Zentalis Pharmaceuticals Insider Sold Shares Worth $118,355, According to a Recent SEC Filing	09/10/23	MT
Zentalis Pharmaceuticals, Inc. Announces Cease of Iris Roth as Chief Operating Officer, Effective October 10, 2023	06/10/23	CI

Chart Zentalis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Companyâs lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.98 USD

Average target price

33.4 USD

Spread / Average Target

+178.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZENTALIS PHARMACEUTICALS, INC.	-20.96%	850M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.22B
ARGENX SE	+0.32%	22.27B
GENMAB A/S	-3.81%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B
LEGEND BIOTECH CORPORATION	-23.95%	8.34B

Bio Therapeutic Drugs